Search
omadacycline; amadacycline (Nuzyra)
Indications:
- community-acquired pneumonia
- acute skin infections & skin structure infections
Dosage:
- IV & oral once daily formulations
injection: 100 mg
tablet: 150 mg
Antimicrobial activity:
- Streptococcus
- Streptococcus pneumoniae
- Streptococcus pyogenes
- Streptococcus anginosus group
- Streptococcus anginosus
- Streptococcus intermedius
- Streptococcusconstellatus
- Enterococcus faecalis
- Staphylococcus
- Staphylococcus aureus (MSSA)
- Staphylococcuslugdunensis
- Haemophilus influenzae & Haemophilus parainfluenzae
- Klebsiella pneumoniae
- Legionella pneumophila
- Mycoplasma pneumoniae
- Chlamydophila pneumoniae
- Enterobacter cloacae
Adverse effects:
- nausea, vomiting, diarrhea, constipation
- infusion site reactions,
- elevated serum transaminsases
- elevated serum gamma-glutamyl transferase
- hypertension
- headache
- insomnia
Mechanism of action:
- tetracycline, bacteriostatic
- inhibits bacterial protein synthesis
General
tetracycline (Achromycin, Sumycin, Bristacycline)
Database Correlations
PUBCHEM correlations
References
- Brooks M
FDA Clears Omadacycline (Nuzyra) for Two Infections
Medscape - Oct 03, 2018.
https://www.medscape.com/viewarticle/902885
- Stets R, Popescu M, Gonong JR et al.
Omadacycline for community-acquired bacterial pneumonia.
N Engl J Med 2019 Feb 7; 380:517.
PMID: 30726692
https://www.nejm.org/doi/10.1056/NEJMoa1800201
- O'Riordan W, Green S, Overcash JS et al.
Omadacycline for acute bacterial skin and skin-structure infections.
N Engl J Med 2019 Feb 7; 380:528.
PMID: 30726689
https://www.nejm.org/doi/10.1056/NEJMoa1800170
- Chambers HF.
Omadacycline - he newest tetracycline.
N Engl J Med 2019 Feb 7; 380:588
PMID: 30726683
https://www.nejm.org/doi/10.1056/NEJMe1900188
- HIGHLIGHTS OF PRESCRIBING INFORMATION
NUZYRA (omadacycline) for injection, for intravenous use
NUZYRA (omadacycline) tablets, for oral use
https://www.nuzyra.com/PI.pdf